Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcino...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

beentherebefor Jul. 3 at 4:13 PM

$BCAB anyone see the poster/abstract from Esmo?

2 · Reply

HjalmarTheGreat Jul. 2 at 6:18 PM

$BCAB https://academic.oup.com/oncolo/article/31/Supplement_1/oyag205.037/8712654

0 · Reply

biovaluable Jul. 1 at 7:30 AM

$BCAB chinese scam stock

1 · Reply

SFG1 Jun. 30 at 6:27 PM

$BCAB Possible breakout pending. Needs some volume of course ; )

0 · Reply

gregwiseman Jun. 29 at 6:22 PM

$BCAB market maker is just a mother fucker .go fuck your bitch you are just a fucket son of bitch. My 2k dollars you scamed those from my shares i wish and hope you may use them for buying madicines . Wish this garbage may go bancrupt .

1 · Reply

HjalmarTheGreat Jun. 27 at 12:33 PM

$BCAB Interesting few weeks ahead. -The new trademark will close on July 2nd. -ESMO presentation on July 3rd for BA3182. -Annual meeting July 16th.

0 · Reply

HjalmarTheGreat Jun. 26 at 7:27 PM

$BCAB Yeeps. Just noticed a 400% maintenance requirement to short this thing. Borrow rate isn't that high though. Pretty much locks out the little guys.

1 · Reply

biovaluable Jun. 26 at 5:52 PM

$BCAB add short

1 · Reply

biovaluable Jun. 26 at 9:19 AM

$BCAB planning more short position at 3.7 today.

0 · Reply

biovaluable Jun. 25 at 2:45 PM

$BCAB sucess short!

0 · Reply

BioAtla Proxy statement: Proxy filing

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

BioAtla Proxy statement: Proxy filing

2026-05-18T10:54:19.000Z - 6 weeks ago

Context Therapeutics enters license agreement amendment with BioAtla

CNTX

May 15, 2026, 4:00 PM EDT - 7 weeks ago

BioAtla Quarterly report: Q1 2026

2026-04-02T23:50:53.000Z - 3 months ago

BioAtla trading halted, news pending

2026-03-31T20:45:40.000Z - 3 months ago

BioAtla announces 50-for-1 share consolidation

Mar 31, 2026, 4:06 PM EDT - 3 months ago

BioAtla Announces Share Consolidation

Mar 31, 2026, 4:05 PM EDT - 3 months ago

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 31, 2026, 7:00 AM EDT - 3 months ago

BioAtla Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 3 months ago

BioAtla Slides: Investor presentation

Mar 2, 2026, 7:30 AM EST - 4 months ago

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Mar 2, 2026, 7:00 AM EST - 4 months ago

BioAtla Proxy statement: Proxy Filing

Feb 11, 2026, 7:00 AM EST - 5 months ago

BioAtla Proxy statement: Proxy Filing

Jan 30, 2026, 7:00 AM EST - 5 months ago

BioAtla Proxy statement: Proxy Filing

Jan 16, 2026, 7:00 AM EST - 6 months ago

BioAtla Registration statement: Registration Filing

Jan 15, 2026, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 6 months ago

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Dec 31, 2025, 7:00 AM EST - 6 months ago

BioAtla Proxy statement: Proxy Filing

Dec 5, 2025, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing

Nov 24, 2025, 7:00 AM EST - 7 months ago

BioAtla Proxy statement: Proxy Filing

Nov 21, 2025, 12:25 AM EST - 8 months ago

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 4:30 PM EST - 8 months ago

BioAtla Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

BioAtla Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

BioAtla Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

BioAtla Slides: Q3 2025

Nov 13, 2025, 4:05 PM EST - 8 months ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 8 months ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 8 months ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 9 months ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 9 months ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 9 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 10 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 7, 2025, 4:30 PM EDT - 11 months ago

BioAtla Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

BioAtla Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

BioAtla Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

BioAtla Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 11 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 11 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 7, 2025, 10:00 AM EDT - 1 year ago

BioAtla Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Quarterly report: Q1 2025

May 6, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q1 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

May 6, 2025, 8:00 AM EDT - 1 year ago

BioAtla Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

BioAtla Proxy statement: Proxy Filing

Apr 23, 2025, 10:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 5:05 PM EDT - 1 year ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioAtla Earnings release: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 1 year ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 1 year ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

BioAtla Earnings release: Q3 2024

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Sep 9, 2024, 7:00 AM EDT - 1 year ago

BioAtla Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q2 2024

Jul 25, 2024, 5:39 PM EDT - 2 years ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Jun 5, 2024, 8:00 AM EDT - 2 years ago

BioAtla Transcript: Jefferies 2024 Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 2 years ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q1 2024

May 14, 2024, 4:05 PM EDT - 2 years ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 13, 2024, 9:30 AM EDT - 2 years ago

BioAtla Transcript: The Citizens JMP Life Sciences Conference

May 8, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Apr 24, 2024, 4:35 PM EDT - 2 years ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

BioAtla Proxy statement: Proxy Filing

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings Call Transcript: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Annual report: Q4 2023

Mar 26, 2024, 4:30 PM EDT - 2 years ago

BioAtla Earnings release: Q4 2023

Mar 26, 2024, 4:01 PM EDT - 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 2 years ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 2 years ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Jan 11, 2024, 12:45 PM EST - 2 years ago

BioAtla Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Dec 20, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 2 years ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 1:00 PM EST - 2 years ago

BioAtla Transcript: The JMP Securities Hematology and Oncology Summit

Dec 6, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 2 years ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 2 years ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 2 years ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

beentherebefor Jul. 3 at 4:13 PM

$BCAB anyone see the poster/abstract from Esmo?

2 · Reply

HjalmarTheGreat Jul. 2 at 6:18 PM

$BCAB https://academic.oup.com/oncolo/article/31/Supplement_1/oyag205.037/8712654

0 · Reply

biovaluable Jul. 1 at 7:30 AM

$BCAB chinese scam stock

1 · Reply

SFG1 Jun. 30 at 6:27 PM

$BCAB Possible breakout pending. Needs some volume of course ; )

0 · Reply

gregwiseman Jun. 29 at 6:22 PM

1 · Reply

HjalmarTheGreat Jun. 27 at 12:33 PM

$BCAB Interesting few weeks ahead. -The new trademark will close on July 2nd. -ESMO presentation on July 3rd for BA3182. -Annual meeting July 16th.

0 · Reply

HjalmarTheGreat Jun. 26 at 7:27 PM

$BCAB Yeeps. Just noticed a 400% maintenance requirement to short this thing. Borrow rate isn't that high though. Pretty much locks out the little guys.

1 · Reply

biovaluable Jun. 26 at 5:52 PM

$BCAB add short

1 · Reply

biovaluable Jun. 26 at 9:19 AM

$BCAB planning more short position at 3.7 today.

0 · Reply

biovaluable Jun. 25 at 2:45 PM

$BCAB sucess short!

0 · Reply

biovaluable Jun. 25 at 9:24 AM

$BCAB there is no deal only delisting remain

1 · Reply

biovaluable Jun. 25 at 2:58 AM

$BCAB today add more short position at $3.76

0 · Reply

biovaluable Jun. 24 at 1:51 AM

$BCAB nice shortage! chinese epcam

0 · Reply

biovaluable Jun. 23 at 2:55 AM

$BCAB FXXXX chinese scam stock. J go to jail!

0 · Reply

biovaluable Jun. 23 at 2:55 AM

$BCAB nice short position!

0 · Reply

Nguyentt Jun. 22 at 5:27 PM

$BCAB why it down

1 · Reply

BiotechValues Jun. 22 at 4:26 PM

$BCAB interesting volume coming in. These guys are running on fumes, $6M market cap, and only 1.7M shares outstanding, but hired a bank to monetize assets 4 months ago. Would imagine they announce an outcome soon. Would think the Epcam program would be of interest to someone

2 · Reply

tylerfree Jun. 18 at 5:08 PM

$BCAB what is going to happen here?

1 · Reply

HjalmarTheGreat Jun. 18 at 3:15 PM

$BCAB This is interesting. New Bioatla trademark pending giving them class 5 protection. The old one is a class 42. This will close on July 2nd. The timing is is clearly engineered by a good lawyer. This asset portfolio will be completely de-risked.

1 · Reply

HjalmarTheGreat Jun. 18 at 2:12 PM

$BCAB Published today.

0 · Reply

biovaluable Jun. 18 at 6:56 AM

$BCAB f** jay, go short! epcam data is not available?

0 · Reply

biovaluable Jun. 17 at 9:13 PM

$BCAB nice short position today. When delisting?

0 · Reply

Market Cap	6.94M
Revenue (ttm)	2.00M
Net Income (ttm)	-59.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,980.50%
Debt to Equity Ratio	0.00

Volume	38,100
Avg Vol	48,096
Day's Range	N/A - N/A
Shares Out	1.66M
Stochastic %K	87%
Beta	0.76
Analysts	Hold
Price Target	$10.00